NCT02447419 2022-06-15Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid TumorsSamsung Medical CenterPhase 2 Completed16 enrolled
NCT00025207 2013-01-17Gefitinib in Treating Patients With Malignant MesotheliomaNational Cancer Institute (NCI)Phase 2 Completed40 enrolled
NCT00787410 2012-06-06An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant MesotheliomaAstraZenecaPhase 2 Completed23 enrolled